Safety Study of Viaskin Peanut to Treat Peanut Allergy

Inclusion Criteria: * Physician-diagnosed peanut allergy; * A peanut Skin Prick Test (SPT) with a wheal largest diameter ≥8 mm; * A specific-peanut Immunoglobulin E (IgE) ≥14 kU/L; * Subjects following a strict peanut-free diet. Exclusion Criteria: * Generalized dermatologic disease * Spirometry forced expiratory volume in 1 second (FEV1) \<80% of the predicted value, or peak expiratory flow (PEF) \<80% of predicted value; * Receiving β-blocking agents, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressant therapy; anti-tumor necrosis factor drugs or anti-IgE drugs (such as omalizumab) or any biologic immunomodulatory therapy; * Prior or concomitant history of any immunotherapy to any food allergy (for example EPIT, OIT, SLIT, or specific oral tolerance induction).